Last week, British officials unveiled plans to toss out certain meds from the Cancer Drugs Fund, which covers drugs rejected by the country's cost-effectiveness gatekeepers. Now, the industry is calling for an overhaul in the way pricey cancer drugs are evaluated by the National Institute for Health and Care Excellence.
The U.K.'s National Institute for Health and Care Excellence says it's not planning to recommend a new Crohn's disease treatment from Millennium Pharmaceuticals.
The National Institute for Health and Care Excellence decided to reverse course on a new use for Johnson & Johnson's anti-inflammatory drug Stelara, thanks to a new discount offer.
Back in March, the U.K.'s cost watchdog went where it hasn't yet gone before, asking Alexion, maker of pricey orphan drug Soliris, to justify the drug's high sticker with information on the company's R&D costs. Now, it hasn't yet gotten the response it wants, it says, but it's backing Soliris regardless--once a few conditions are met.
Here's some good news for Lundbeck in an otherwise bleak week: The U.K.'s cost watchdog has endorsed its alcohol-dependence treatment, Selincro.
The U.K.'s cost gatekeeper is notoriously strict when it comes to approving drugs, shooting down meds based on strict cost-effectiveness standards or saddling them with restrictions. But cancer drugs could face the toughest road ahead, as a new report shows that the National Institute of Health and Care Excellence is less likely to green-light the meds compared to other classes of drugs.
The U.K.'s cost-effectiveness gatekeepers have flip-flopped on Novartis' Xolair before, withdrawing support for the drug in 2012 before expanding its approval for asthma the following year. Now, the National Institute for Health and Clinical is asking the drugmaker to pony up more information about the product before recommending it to treat chronic spontaneous urticarial (CSU), or psoriasis.
Bayer's Xarelto, which has been cruising along since it joined a new class of warfarin replacement therapies on the market, has faced a rare stumbling block in acute coronary syndrome--an indication the FDA has denied it on three separate occasions. But across the pond, it's picked up a nod in some ACS patients from the U.K.'s cost-effectiveness gatekeeper.
Drugmakers are accustomed to grappling with government payers and PBMs over prices. But a pricing fight directly with patients? That's not your everyday occurrence.
The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from the gatekeeper? Celgene's Imnovid.